EBAMED
18.2.2021 13:02:04 CET | Business Wire | Press release
EBAMed SA, developer of medical technologies to transform the treatment of cardiac arrhythmias, has appointed experienced specialist Marina Izzo as Chief Executive Officer (CEO). Mrs. Izzo will set the vision for EBAMed’s technology and lead the effort for the next financing round, planned for 2022. Former CEO and co-founder, Adriano Garonna has transitioned to Chief Technology Officer (CTO) and maintains a role on the company’s Board of Directors.
“Marina has strong experience in leading medical device businesses and developing the market for groundbreaking cardiovascular technologies in Europe, North America and China,” said Mr. Giovanni Leo, Chairman of the Board. “Her experience will be invaluable as we realize our mission to shift the paradigm in electrophysiology (EP) from catheter-based ablation therapies to non-invasive EP procedures.”
Mrs. Izzo served as CEO for Cardionovum, an innovative developer of drug coated balloon technology. Prior to that, she was Senior Director of Sales and Marketing at Symetis SA (now part of Boston Scientific), where she established the company as a key competitor in the transcatheter aortic valve implantation (TAVI) market. She has held several leadership roles with Medtronic in Europe and with St. Jude Medical, including Marketing Director for the EMEA Atrial Fibrillation (AF) business. Mrs. Izzo is a graduate of Bocconi University of Milan.
“Many patients fail or cannot undergo conventional invasive therapies such as ablation,” said Mrs. Izzo. “I am very excited to continue exploring the potential of radiation oncology therapies in cardiac medicine and to realize EBAMed’s mission to change the lives of patients living with cardiac arrhythmias”.
Some 53 million people globally1 experience some type of cardiac arrhythmia. For older persons with a history of heart disease, arrhythmia can lead to serious medical complications. The development of a radiation therapy approach, combined with an unique motion monitoring and gating solution to improve target definition and tracking accuracy, could be of substantial value in providing alternative therapy to either drug therapy or catheter-based ablation, and to reduce radiation to innocent myocardium.
About EBAMed
EBAMed is an early-stage, private medical device company. EBAMed is developing a cardiac ultrasound product to improve radioablation for Ventricular Tachycardia, a growing clinical need in the face of the prevalence of heart disease, and aging populations. For more information, visit https://eba-med.com
1 JPMorgan 39th Annual Healthcare Conference, January 2021 - Virtual
View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005060/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Accertify Launches Global Air Travel Fraud Report Revealing Where Booking-Stage Pressure Is Most Concentrated22.4.2026 14:00:00 CEST | Press release
Q1 2026 analysis shows significant variation in prevented fraud rates by origin city, with higher concentrations across parts of Latin America, Africa, the Middle East, and South & Southeast Asia Accertify, a leading unified risk decisioning platform provider, today announced the release of its Global Air Travel Fraud Report: Q1 2026, a quarterly analysis examining how fraud risk in airline bookings varies by route origin across global markets. Based on more than 180 million airline booking transactions processed between January and March 2026, the report analyzes fraud rates by departure city as a proxy for route origin, offering airlines a practical view of where fraud prevention systems are intervening most frequently at the point of booking. The Q1 2026 findings show that fraud risk in airline bookings is unevenly distributed across markets, with meaningful differences emerging by region and by origin city. Routes originating in North America and Australia continue to exhibit consi
NetApp Strengthens its Collaboration with Google Cloud on Unified Google Cloud Storage for File and Block22.4.2026 14:00:00 CEST | Press release
Announced at Next ‘26, Flex Unified service for Google Cloud NetApp Volumes is now generally available NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today shared new innovations that help customers better leverage their enterprise data, by tapping into the benefits of AI with Google Cloud. Enterprises want to use their existing data for AI, but moving and managing that data across multiple environments is complex, slow, and expensive. NetApp is simplifying this with Google Cloud. With Google Cloud NetApp Volumes, customers can run enterprise applications, databases, and AI workloads in the cloud without rearchitecting or rebuilding their environments. “Customers can move their enterprise data, whether block or file, into Google Cloud NetApp Volumes easily, and once it’s there, they can use Google Cloud services, including for AI, directly on that data without needing to move or duplicate it again,” said Pravjit Tiwana, Senior Vice President and General Manager of
NetApp Partners with Google Cloud to Adopt AI-Driven Operations22.4.2026 14:00:00 CEST | Press release
Google Gemini Enterprise drives productivity for NetApp sales and product development NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced a strategic evolution in its partnership with Google Cloud, which has enabled enterprises to drive AI innovation with their own data stored in the NetApp data platform. After seeing the productivity and innovation benefits customers experienced using Gemini Enterprise integrated with their data in Google Cloud NetApp Volumes, NetApp has adopted Gemini Enterprise to help increase productivity in its internal product development and sales operations. With the adoption of Google Cloud AI technologies, NetApp is expanding its leadership in enterprise-grade AI innovation, not just enabling AI workloads but acting as an AI practitioner. NetApp customers will benefit from the AI-powered gains in productivity and innovation. “AI is an imperative for enterprise success, and NetApp is committed to leading by example,” said Césa
ExaGrid Named a Finalist for the Storage Awards 202622.4.2026 14:00:00 CEST | Press release
ExaGrid Product Line, Partner Program, and Team Nominated in 16 Categories for “The Storries XXIII” ExaGrid®, the world’s largest independent backup storage vendor providing Tiered Backup Storage with the most Comprehensive Security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced that it has been nominated in 16 categories for the 23rd annual Storage Awards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422235829/en/ ExaGrid has become a finalist in the following categories: Storage Innovator of the Year Immutable Storage Company of the Year Storage Industry Champion – Commercial Storage Industry Champion – Marketing Channel Excellence Award AI Data Storage Innovator of the Year Cyber Resilient Storage Company of the Year Ransomware Product of the Year Data Protection Company of the Year Enterprise Backup Hardware Vendor of the Year Object Storage Vendor of the Year Storage Optimisation Compan
Samsung Biologics Union Holds First Rally, Warns of May 1 Strike22.4.2026 13:56:00 CEST | Press release
Union estimates about 2,200 participants at one-hour event outside Bio Campus 1 Samsung Biologics’ labor union held its first rally on Tuesday and said it would move ahead with a strike on May 1 if management continues to reject meaningful talks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422754766/en/ Union members gather at a rally organized by the Samsung Biologics labor union outside Bio Campus 1 in Songdo, Incheon, on April 22, ahead of a planned May 1 strike. The rally, held for about an hour outside the main gate of the company’s Bio Campus 1 in Songdo, drew about 2,200 participants, according to the union. The event marks an escalation in a labor dispute that union leaders say is no longer limited to a small number of bargaining items, but instead concerns broader questions about accountability and decision-making within the company. Park Jaesung, chair of the Samsung Biologics union, said management had faile
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom